Century therapeutics reports second quarter 2025 financial results and provides business update

Patient dosing ongoing in calipso-1 trial; on track to report clinical data for cnty-101 in patients with b-cell-mediated autoimmune diseases by year-end 2025 cnty-308, a car-it cell therapy functionally comparable to primary t cells, now in ind-enabling studies as a potential treatment for b-cell-mediated diseases; program expected to progress into the clinic in 2026 dr. brent pfeiffenberger, ceo, appointed to board chair cash runway extended into fourth quarter 2027 philadelphia, aug. 14, 2025 (globe newswire) -- century therapeutics, inc. (‘century', nasdaq: ipsc), an innovative biotechnology company developing induced pluripotent stem cell (ipsc)-derived cell therapies in autoimmune disease and cancer, today reported financial results for the second quarter ended june 30, 2025, and provided a business update. “in the first half of 2025, we made important business decisions to ensure our capital resource allocation and pipeline development activities are centered on potentially transformational cell therapy candidates and technologies.
CNTY Ratings Summary
CNTY Quant Ranking